Your browser doesn't support javascript.
loading
Rate of breast biopsy referrals in female BRCA mutation carriers aged 50 years or more: a retrospective comparative study and matched analysis.
Pomerantz, Adi; Tsoref, Daliah; Grubstein, Ahuva; Wadhawker, Sonya; Rapson, Yael; Gadiel, Itay; Goldvaser, Hadar; Feldhamer, Ilan; Hammerman, Ariel; Shochat, Tzipora; Sharon, Eran; Kedar, Inbal; Yerushalmi, Rinat.
Afiliação
  • Pomerantz A; Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva, 4941492, Israel.
  • Tsoref D; Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva, 4941492, Israel.
  • Grubstein A; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 69978, Israel.
  • Wadhawker S; Imaging Department, Rabin Medical Center, Beilinson Hospital, Petah Tikva, 4941492, Israel.
  • Rapson Y; Surgery Department, Breast Cancer Unit, Rabin Medical Center, Beilinson Hospital, Petah Tikva, 4941492, Israel.
  • Gadiel I; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 69978, Israel.
  • Goldvaser H; Imaging Department, Rabin Medical Center, Beilinson Hospital, Petah Tikva, 4941492, Israel.
  • Feldhamer I; Imaging Department, Rabin Medical Center, Beilinson Hospital, Petah Tikva, 4941492, Israel.
  • Hammerman A; Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva, 4941492, Israel.
  • Shochat T; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 69978, Israel.
  • Sharon E; Chief Physician's Office, Clalit Health Services Headquarters, Tel Aviv, 6340412, Israel.
  • Kedar I; Chief Physician's Office, Clalit Health Services Headquarters, Tel Aviv, 6340412, Israel.
  • Yerushalmi R; Statistical Consulting Unit, Rabin Medical Center, Beilinson Hospital, Petah Tikva, 4941492, Israel.
Breast Cancer Res Treat ; 193(2): 507-514, 2022 Jun.
Article em En | MEDLINE | ID: mdl-35391652
PURPOSE: To evaluate the total biopsy and positive biopsy rates in women at high risk of breast cancer compared to the general population. METHODS: The study group consisted of 330 women with pathogenic variants (PVs) in BRCA1/2 attending the dedicated multidisciplinary breast cancer clinic of a tertiary medical center in Israel. Clinical, genetic, and biopsy data were retrieved from the central healthcare database and the medical files. Patients aged 50 years or older during follow-up were matched 1:10 to women in the general population referred for routine breast cancer screening at the same age, as recommended by international guidelines. The groups were compared for rate of biopsy studies performed and percentage of positive biopsy results. Matched analysis was performed to correct for confounders. RESULTS: The total biopsy rate per 1000 follow-up years was 61.7 in the study group and 22.7 in the control group (p < 0.001). The corresponding positive biopsy rates per 1000 follow-up years were 26.4 and 2.0 (p < 0.001), and the positive biopsy percentages, 42.9% and 8.7% (p < 0.0001). CONCLUSION: Women aged 50 + years with PVs in BRCA1/2 attending a dedicated clinic have a 2.7 times higher biopsy rate per 1000 follow-up years, a 13.2 times higher positive biopsy rate per 1000 follow-up years, and a 4.9 times higher positive biopsy percentage than same-aged women in the general population.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Diagnostic_studies / Guideline / Observational_studies / Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Israel

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Diagnostic_studies / Guideline / Observational_studies / Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Israel